Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20979250 | 0.97 | USP2 (0.42) | USP2CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL9322304 | 0.95 | CARM1 (0.41) | USP2CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL21730510 | 0.93 | HRH3 (0.44) | USP2CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL21730428 | 0.93 | HRH3 (0.44) | USP2CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL21120540 | 0.93 | USP2 (0.46) | USP2CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL20979276 | 0.92 | CARM1 (0.39) | USP2CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL26941612 | 0.92 | CARM1 (0.41) | USP2CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL21730448 | 0.91 | HRH3 (0.43) | USP2CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL21730424 | 0.91 | HRH3 (0.41) | USP2CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL14524678 | 0.89 | CARM1 (0.41) | USP2CARM1PRMT6PRMT8HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731986-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230029557-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-02-02 | — | — | US | disclosed |
| US-11066420-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200055875-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029557-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | ACP1, PTPRCAP, PTPRO | USP2 1136/4885CARM1 3967/4885PRMT6 2400/4885 |
| US-11731986-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | ACP1, PTPRCAP, PTPRO | USP2 1136/4885CARM1 3967/4885PRMT6 2400/4885 |
| US-20200055875-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | ACP1, PTPRCAP, PTPRO | USP2 1136/4885CARM1 3967/4885PRMT6 2400/4885 |
| US-11066420-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | ACP1, PTPRCAP, PTPRO | USP2 1136/4885CARM1 3967/4885PRMT6 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.